Clinical trial Recruiting at 1 site Interventional Ages 18 to 95

Vascular closure versus manual compression after atrial fibrillation ablation

Official title: Prospektiv Randomisierter Vergleich Der Manuellen Und Leistenkompression Mittels Naht Oder Einsatz Eines venösen Verschlusssystems Zur Blutstillung Nach Vorhofflimmerablation (VASC-AF)

Run by Asklepios proresearch · NCT07414121 · Data updated 2026-11-12

This will test whether the VASCADE MVP vascular closure device lets adults having pulmonary vein isolation for atrial fibrillation walk sooner than manual compression or a figure-of-8 suture.

Quick facts

Study typeInterventional
Ages18 Years to 95 Years
SexAll
Enrollment100 (estimated)
SponsorAsklepios proresearch
Industry-sponsored
Locations1 site (Hamburg)
StatusRecruiting
StartedApril 22, 2025
Main results expectedOctober 1, 2026
Study endsDecember 1, 2026
Registry record updatedFebruary 17, 2026
Trial IDNCT07414121 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) scheduled for pulmonary vein isolation (catheter ablation) for atrial fibrillation who meet local medical eligibility criteria are the intended participants.

Probably not a fit

People under 18, those not using femoral venous access, or patients with high bleeding risk or anatomy unsuitable for the device may not receive benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults undergoing pulmonary vein isolation for atrial fibrillation at Asklepios Klinik Altona will receive either the VASCADE MVP vascular closure device or standard manual compression/figure-of-8 suture for femoral venous access closure. The primary efficacy endpoint is time to ambulation, defined as the time from removal of the final sheath or closure device until the patient can stand and walk 20 ft without venous re-bleeding; the primary safety endpoint is major periprocedural adverse events requiring medical intervention before hospital discharge. Study staff at participating sites are trained to apply consistent endpoint definitions to preserve comparability. The trial will also record minor vascular complications and feasibility measures such as device use and need for additional hemostatic measures.

Why it matters

Potential benefit: If successful, the device could let patients get out of bed and move sooner after AF ablation, shortening recovery time and potentially enabling earlier discharge.

How similar studies have gone: Vascular closure devices have been used successfully in other catheterization settings, but evidence specifically comparing venous closure devices versus manual compression after AF ablation is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* AF ablation

Exclusion Criteria:

* \<18 years

Where it's running

  • Asklepios Klinik Altona
    Hamburg, Germany
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.